Phospho-CDC25A (T507) Antibody

What is CDC25A and what is the significance of phosphorylation at T507?

CDC25A is a dual-specificity protein phosphatase that functions as a dosage-dependent inducer of mitotic progression. It directly dephosphorylates and activates cyclin-dependent kinases including CDK1, CDK2, CDK4, and CDK6, promoting cell cycle progression . Phosphorylation at threonine 507 (T507) is particularly significant as it facilitates 14-3-3 protein binding, which subsequently inhibits interactions between CDC25A and its mitotic substrate cyclin B1-CDK1 . This regulatory mechanism serves as a checkpoint to prevent premature entry into mitosis, ensuring genomic integrity during cell division. The Chk1 kinase has been identified as responsible for phosphorylating CDC25A at T507 in vitro, establishing the Chk1/CDC25A/14-3-3 pathway as a critical regulator of cell cycle fidelity .

What applications are Phospho-CDC25A(T507) antibodies suitable for?

Phospho-CDC25A(T507) antibodies have been validated for multiple experimental applications, making them versatile tools in cell cycle research. The primary validated applications include:

• Western Blot (WB): Typically used at dilutions ranging from 1:250 to 1:1000, depending on the specific antibody formulation

• Immunofluorescence (IF): Generally recommended at 1:25 dilution for optimal signal-to-noise ratio

• Immunohistochemistry on paraffin-embedded sections (IHC-P): Functioning at dilutions between 1:50-1:200, allowing visualization of phosphorylated CDC25A in tissue contexts

When designing experiments, researchers should consider that these antibodies demonstrate confirmed reactivity with human samples, with predicted cross-reactivity for bovine, mouse, and rat samples based on sequence homology .

What are the optimal storage and handling conditions for Phospho-CDC25A(T507) antibodies?

To maintain antibody integrity and performance across multiple experiments, proper storage and handling are essential:

The standard formulation of these antibodies includes PBS with 0.09% (W/V) sodium azide as a preservative . To prevent performance degradation, it's critical to avoid repeated freeze-thaw cycles, which is why dividing the antibody into small working aliquots prior to freezing is strongly recommended . When removing from storage, thaw aliquots completely before use and mix gently to ensure homogeneity.

How can researchers validate the specificity of Phospho-CDC25A(T507) antibody?

Validating antibody specificity is crucial for ensuring experimental rigor. For Phospho-CDC25A(T507) antibodies, consider these methodological approaches:

• Peptide Competition Assay: Pre-incubate the antibody with the phosphopeptide used for immunization (synthetic phosphopeptide corresponding to residues surrounding T507 of human CDC25A). A specific antibody will show reduced or eliminated signal when the competing peptide is present .

• Phosphatase Treatment Control: Treat one sample with lambda phosphatase before immunoblotting. Loss of signal after phosphatase treatment confirms phospho-specificity.

• Genetic Validation: Compare signal between wild-type samples and those expressing CDC25A with T507A mutation. The antibody should not recognize the mutated form where the phosphorylation site has been eliminated .

• Stimulus-Response Testing: Treat cells with agents known to activate Chk1 (e.g., DNA damaging agents) and observe increased T507 phosphorylation signal, confirming the antibody detects physiologically relevant changes in phosphorylation status.

What is the functional significance of CDC25A T507 phosphorylation in cell cycle regulation?

The phosphorylation of CDC25A at T507 represents a critical regulatory mechanism in cell cycle control with multiple functional consequences:

• 14-3-3 Protein Binding: Phosphorylation at T507 creates a binding site for 14-3-3 proteins, which sequester CDC25A and inhibit its phosphatase activity .

• Inhibition of Substrate Binding: This phosphorylation inhibits interactions between CDC25A and its mitotic substrate cyclin B1-CDK1, preventing premature activation of mitotic kinases .

• Cell Cycle Checkpoint Control: Mutation of T507 to alanine (T507A) enhances CDC25A biological activity, resulting in more efficient binding to cyclin B1, increased activation of cyclin B1-CDK1, and premature entry into mitosis . This demonstrates that T507 phosphorylation functions as a regulatory mechanism to prevent cells from entering mitosis before completing DNA replication.

• Integration with DNA Damage Response: The Chk1/CDC25A/14-3-3 pathway serves as a surveillance mechanism to ensure genomic integrity during cell division by preventing premature mitotic entry, particularly following DNA damage .

Experimental evidence using the T507A mutation has established that this phosphorylation site plays a non-redundant role in CDC25A regulation that cannot be fully compensated by other phosphorylation events.

How does CDC25A phosphorylation status differ between normal and cancer cells?

CDC25A phosphorylation patterns, including at T507, show distinct differences between normal and cancer tissues:

• Overexpression in Cancer: CDC25A is frequently overexpressed in various types of cancer, contributing to accelerated cell cycle progression and genomic instability .

• Altered Phosphorylation Balance: While normal cells maintain tight regulation of CDC25A through phosphorylation-dependent degradation, cancer cells often exhibit dysregulated phosphorylation patterns, including at T507.

• Immunohistochemical Evidence: Immunohistochemical analysis using Phospho-CDC25A(T507) antibodies has revealed distinct staining patterns in human lung carcinoma tissues, suggesting altered phosphorylation status in cancer contexts .

• Checkpoint Adaptation: Cancer cells may develop mechanisms to override T507 phosphorylation-dependent inhibition, allowing continued proliferation despite the presence of genomic damage that would normally trigger cell cycle arrest.

These differences make phosphorylation-specific CDC25A antibodies valuable tools for studying cancer-specific alterations in cell cycle regulation and potential therapeutic vulnerabilities.

What are the recommended protocols for using Phospho-CDC25A(T507) antibody in Western blot applications?

For optimal Western blot results with Phospho-CDC25A(T507) antibodies, follow these methodological recommendations:

Sample Preparation:

• Lyse cells in a buffer containing phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate) to preserve phosphorylation status.

• Include protease inhibitors to prevent general protein degradation.

• Process samples quickly and maintain cold temperatures throughout.

Electrophoresis and Transfer:

• Load 20-50 μg total protein per lane.

• Use 8-10% SDS-PAGE gels for optimal resolution of CDC25A (calculated MW: 59 kDa).

• Transfer to PVDF or nitrocellulose membranes using standard methods.

Antibody Incubation:

• Block membranes in 5% BSA in TBST (not milk, which contains phosphatases).

• Dilute primary antibody 1:250-1:1000 in blocking buffer .

• Incubate overnight at 4°C with gentle agitation.

• Wash thoroughly with TBST before secondary antibody incubation.

Controls to Include:

• Positive control: Lysate from cells treated with agents that activate Chk1 (e.g., UV, hydroxyurea).

• Negative control: Lysate from cells expressing CDC25A(T507A) mutant.

• Loading control: Probe for total CDC25A to normalize phospho-signal.

When troubleshooting weak signals, consider enriching phosphoproteins through immunoprecipitation prior to Western blot analysis.

How can Phospho-CDC25A(T507) antibody be used to investigate the role of CDC25A in apoptosis?

CDC25A has dual roles in cell proliferation and apoptosis regulation. Researchers investigating apoptotic functions can employ these methodological approaches:

• Co-immunoprecipitation Studies: Use Phospho-CDC25A(T507) antibodies to examine the interaction between phosphorylated CDC25A and Apoptosis Signal-regulating Kinase 1 (ASK1). Research suggests that nitrosative stress can decouple CDC25A from ASK-1, potentially priming ASK-1 for activation and sensitizing cells to chemotherapeutic-induced apoptosis .

• Apoptosis Sensitization Assays: Investigate whether altered CDC25A phosphorylation status at T507 affects cellular sensitivity to apoptosis inducers. This can be accomplished by comparing wild-type cells to those expressing phosphomimetic (T507D) or phospho-deficient (T507A) CDC25A mutants.

• Checkpoint Analysis: Examine how CDC25A T507 phosphorylation affects cell cycle checkpoints after DNA damage by measuring:

  • Activation of downstream apoptotic markers (cleaved caspases, PARP cleavage)

  • Cell viability (MTT, XTT assays)

  • Specific apoptosis markers (Annexin V staining, TUNEL assay)

• Chemosensitivity Testing: Determine if pharmacological or genetic manipulation of CDC25A phosphorylation status alters sensitivity to chemotherapeutic agents. Research indicates that nitrosative stress-induced changes in CDC25A can sensitize cells to cisplatin .

What considerations are important when using Phospho-CDC25A(T507) antibody in cancer research models?

When designing experiments for cancer research using Phospho-CDC25A(T507) antibodies, consider these methodological factors:

• Cell Line Selection: Different cancer types and cell lines may exhibit varied levels of CDC25A expression and phosphorylation. Compare multiple cancer cell lines to normal cell controls for comprehensive analysis.

• Microenvironmental Factors: Consider how tumor microenvironmental conditions (hypoxia, inflammation, nutrient deprivation) affect CDC25A phosphorylation. For example, nitrosative stress conditions can affect CDC25A function through mechanisms distinct from canonical checkpoint pathways .

• Therapeutic Relevance: Investigate whether CDC25A T507 phosphorylation status correlates with sensitivity to specific cancer therapies:

  • DNA damaging agents

  • Cell cycle inhibitors

  • Chk1 inhibitors (which would directly affect T507 phosphorylation)

• Patient Sample Analysis: When examining patient-derived samples:

  • Use appropriate antigen retrieval methods for IHC-P applications

  • Consider tumor heterogeneity by analyzing multiple regions

  • Correlate phosphorylation status with clinical outcomes

• Resistance Mechanisms: Explore whether alterations in CDC25A T507 phosphorylation contribute to therapy resistance by comparing sensitive and resistant cell populations.

How does nitrosative stress affect CDC25A T507 phosphorylation and function?

Nitrosative stress introduces a complex layer of regulation to CDC25A function that differs from canonical cell cycle checkpoint mechanisms:

• Selective Pathway Inhibition: Nitrosative stress can selectively inhibit both phosphatase-dependent and phosphatase-independent activities of CDC25A . This includes potential effects on CDC25A phosphorylation at T507, though this relationship requires further investigation.

• Apoptotic Threshold Regulation: Research indicates that nitrosative stress can decouple CDC25A from ASK-1, potentially priming ASK-1 for activation. This suggests that CDC25A phosphorylation status, including at T507, may influence the apoptotic threshold in cells experiencing nitrosative challenge .

• Paradoxical Effects: While nitrosative stress can inhibit DNA synthesis, restoration of CDC25A activity in nitrosatively-challenged cells did not alter this inhibition, distinguishing nitrosative inhibition of DNA synthesis from the canonical intra-S-phase checkpoint . This suggests complex interactions between nitrosative stress, CDC25A phosphorylation, and cell cycle regulation.

• Therapeutic Implications: Understanding how nitrosative stress affects CDC25A T507 phosphorylation could reveal mechanisms by which tumors exposed to inflammatory microenvironments (with high nitric oxide levels) develop resistance to cell cycle checkpoint controls .

Research methodology to investigate these relationships should include comparative phosphorylation analysis using Phospho-CDC25A(T507) antibodies under normal and nitrosative stress conditions, coupled with functional readouts of CDC25A activity.

How do different phosphorylation sites on CDC25A interact with T507 phosphorylation?

CDC25A regulation involves multiple phosphorylation sites that function in concert. Understanding their interrelationship requires sophisticated experimental approaches:

• Phosphorylation Site Mapping: Mass spectrometry analysis can identify which phosphorylation sites (including T507) are simultaneously occupied under different cellular conditions.

• Sequential Phosphorylation Analysis: Investigate whether phosphorylation at T507 is a prerequisite for, or consequence of, phosphorylation at other sites such as S178, which also facilitates 14-3-3 binding .

• Mutational Analysis Strategies: Compare the effects of single (T507A) versus combined phosphosite mutations (e.g., T507A/S178A) on CDC25A function, stability, and localization to determine cooperative or antagonistic relationships.

• Kinase-Phosphatase Networks: Examine how different upstream kinases (beyond Chk1) may influence T507 phosphorylation under varied cellular contexts, including:

  • Growth factor signaling

  • Metabolic stress

  • Inflammatory conditions

  • Development and differentiation

These studies require sophisticated use of phospho-specific antibodies, including Phospho-CDC25A(T507), in combination with genetic and pharmacological approaches.

What are the emerging techniques for studying dynamic changes in CDC25A T507 phosphorylation?

Advanced methodologies for investigating real-time dynamics of CDC25A T507 phosphorylation include:

• FRET-Based Biosensors: Development of fluorescence resonance energy transfer (FRET) biosensors incorporating the T507 region of CDC25A could enable real-time visualization of phosphorylation/dephosphorylation dynamics in living cells.

• Microfluidic Single-Cell Analysis: Combining microfluidic technologies with phospho-specific antibody detection allows examination of cell-to-cell variation in T507 phosphorylation levels within populations.

• Bimolecular Fluorescence Complementation (BiFC): This technique could visualize interactions between phosphorylated CDC25A and 14-3-3 proteins in live cells, providing spatial and temporal information about when and where T507 phosphorylation affects protein-protein interactions.

• Optogenetic Control: Light-inducible kinase systems could enable precise temporal control of CDC25A phosphorylation, allowing detailed investigation of downstream consequences.

• Proximity Ligation Assays (PLA): This super-resolution technique can detect endogenous interactions between phosphorylated CDC25A and its binding partners with higher sensitivity than conventional co-immunoprecipitation.

These cutting-edge approaches, coupled with traditional biochemical methods using Phospho-CDC25A(T507) antibodies, promise to reveal new insights into the dynamic regulation of CDC25A in normal and pathological contexts.